Tresiba Cost in Colorado 2026: Prices, Insurance, Medicaid, and Compounding

What Is Insulin Degludec (Tresiba)?

Insulin degludec is an ultra-long-acting basal insulin analog manufactured by Novo Nordisk and sold in the United States under the brand name Tresiba. The FDA approved it in September 2015 for adults with type 1 and type 2 diabetes, and in 2019 extended that approval to pediatric patients as young as one year old [1]. Its half-life exceeds 25 hours, producing a flat, steady serum concentration curve with a duration of action beyond 42 hours after a single dose [2].

That pharmacokinetic profile distinguishes insulin degludec from insulin glargine U-100 (Lantus) and insulin glargine U-300 (Toujeo). Head-to-head data from the SWITCH-1 and SWITCH-2 crossover trials (combined N=, each crossover arm approximately 500 patients) demonstrated statistically significant reductions in nocturnal hypoglycemia with degludec versus glargine U-100 [3]. The FDA prescribing label states the drug is available as 100 units/mL and 200 units/mL prefilled pens (FlexTouch) [1].

For Colorado patients with diabetes, understanding cost pathways matters as much as the clinical profile. The sections below dissect every major access route.

Tresiba List Price vs. What Colorado Patients Actually Pay

The list price and the out-of-pocket price are two very different numbers. Novo Nordisk's wholesale acquisition cost for Tresiba FlexTouch (5 pens, 100 units/mL) is approximately $510 per month as of 2026 [4]. Virtually no cash-pay patient in Colorado pays that figure.

GoodRx and similar pharmacy benefit managers negotiate rebated rates. Across Colorado retail chains including King Soopers Pharmacy, Walgreens, and Walmart Pharmacy, the average discounted cash price for a 30-day supply of insulin degludec runs near $35 per month in 2026 [5]. That price applies to patients without insurance or whose insurance does not cover Tresiba.

The American Diabetes Association's 2024 Standards of Care note that "insulin affordability remains a serious problem for many people with diabetes," and the organization has called for out-of-pocket caps to be applied broadly across insulin types [6]. Colorado enacted SB 23-093 in 2023, capping monthly out-of-pocket insulin costs at $35 for state-regulated health plans, a policy that may apply to Tresiba if it is on a plan's formulary [7].

Patients on Medicare Part D face a separate structure. The Inflation Reduction Act's $35 monthly insulin cap for Medicare beneficiaries took effect January 1, 2023, and applies to all covered insulin products, including Tresiba when listed on a plan's formulary [8]. Confirm formulary placement with your specific Part D plan before assuming the cap applies.

Colorado Medicaid Coverage for Tresiba

Colorado Medicaid (Health First Colorado) covers Tresiba for type 1 diabetes but does not include it on the preferred drug list for type 2 diabetes as of 2026 [9]. That distinction matters for roughly 90% of Colorado's diabetes population, because approximately 90 to 95% of all diabetes cases are type 2 [10].

For type 2 patients on Health First Colorado, a prescribing clinician may submit a prior authorization (PA) request documenting that preferred basal insulins (typically insulin glargine biosimilars) have failed or are contraindicated. PA approval rates for non-preferred basal insulins vary, and there is no published Colorado-specific approval rate for degludec PAs. Clinicians at HealthRX who prescribe for Medicaid-enrolled patients document nocturnal hypoglycemia frequency, fasting glucose variability (typically measured across 14 or more days of continuous glucose monitoring), and allergy or intolerance to preferred agents.

The Colorado Department of Health Care Policy and Financing publishes its preferred drug list quarterly at the HCPF website [9]. Patients should verify the current PDL status before any appointment, because formulary placements change. The 2024 ADA Standards of Care recommend that "if cost is a major issue, human insulins may be considered," and they list insulin degludec among newer analogs whose cost may limit access [6].

How the Novo Nordisk Patient Assistance and Savings Programs Work

Novo Nordisk runs two distinct affordability mechanisms that Colorado patients can use: the Tresiba savings card (commercial insurance) and the NovoCare Patient Assistance Program (uninsured or underinsured).

The savings card caps co-pays at $99 per month for eligible commercially insured patients. Eligibility excludes federal program enrollees such as Medicare and Medicaid recipients. Patients must have a valid prescription and be residents of the United States [11]. The card is renewed annually and requires re-enrollment each calendar year.

NovoCare provides free Tresiba to qualifying uninsured or underinsured patients whose household income falls at or below 400% of the federal poverty level. In 2026, that threshold is approximately $60,240 for a single-person household [12]. Applications are submitted online or by phone, and Novo Nordisk ships product directly to the prescribing clinician's office or, in some cases, the patient's home.

Colorado also has the Colorado Medication Assistance Program (CMAP), a state-administered service that helps residents manage manufacturer PAPs including Novo Nordisk's program [13]. CMAP case managers handle paperwork on behalf of patients who find direct enrollment difficult.

Compounded Insulin Degludec in Colorado: What Is Legal

Compounded insulin degludec is legally available to Colorado patients through state-licensed 503A compounding pharmacies. 503A pharmacies compound patient-specific prescriptions under state board of pharmacy oversight rather than FDA manufacturing standards [14]. A licensed prescriber must write an individualized prescription; bulk compounding for office stock is not permitted under 503A.

The FDA has addressed compounded insulin products in draft guidance documents. The agency has noted that "copies of commercially available products" raise additional scrutiny under section 503A of the FD&C Act [15]. However, that scrutiny has not resulted in a blanket prohibition on compounded basal insulin, and 503A pharmacies in Colorado continue to prepare insulin degludec under individual prescriptions.

Cost is the primary driver of interest in compounded insulin degludec. A 503A pharmacy compounding degludec from pharmaceutical-grade active pharmaceutical ingredient may charge $0 to the patient when costs are absorbed by a third party or membership model, or charge a dispensing fee substantially below the $510 list price [5]. Patients considering compounded insulin should confirm the pharmacy's 503A licensure with the Colorado State Board of Pharmacy [16], verify that the API supplier has a valid Drug Master File with the FDA, and discuss clinical equivalence with their prescribing clinician.

Compounded products are not FDA-approved, do not carry the same sterility and potency assurance as manufactured Tresiba, and are not bioequivalent substitutes in a regulatory sense. The clinical decision to use compounded versus brand insulin degludec should involve a physician review of individual patient risk factors including injection technique, glucose monitoring access, and history of hypoglycemia.

Telehealth Prescribing of Tresiba in Colorado

Colorado law permits telehealth prescribing of non-controlled medications including basal insulins. Tresiba is not a controlled substance; it is a prescription-only drug under federal law [1]. A licensed Colorado prescriber may issue an insulin degludec prescription following a telehealth visit that meets Colorado's standard of care requirements, which include a documented clinical evaluation, a diagnosis, and a treatment plan [17].

The Colorado Medical Practice Act does not require an in-person physical examination before prescribing insulin for patients with an established diabetes diagnosis, though individual prescriber judgment governs the adequacy of a telehealth evaluation [17]. For new-to-insulin patients, many clinicians prefer at least one visit that includes review of injection technique, either in person or via video with the patient demonstrating injection on camera.

HealthRX's Colorado-licensed clinicians can prescribe Tresiba via video visit, route the prescription to a pharmacy of the patient's choice, and provide asynchronous dose titration support using uploaded glucose logs or CGM data exports. The ADA's 2024 Standards of Care recognize telehealth as an effective delivery mode for diabetes management [6].

Insurance Coverage for Tresiba in Colorado

Coverage varies sharply by plan type. The table below maps common Colorado insurance categories to typical Tresiba formulary status.

Colorado Health Exchange plans (Connect for Health Colorado): Tresiba appears on some silver and gold tier formularies as a non-preferred brand, typically at a tier-3 or tier-4 co-pay before the deductible is met. After the deductible, co-pays range from $60 to $150 per fill depending on plan. The Colorado $35 insulin cap under SB 23-093 applies to state-regulated individual and small-group plans once the drug is a covered benefit [7].

Employer-sponsored plans regulated under ERISA: ERISA-governed plans are exempt from state-level cost caps including SB 23-093. Coverage and co-pays depend entirely on the employer's pharmacy benefit manager (PBM) contract. CVS Caremark, Express Scripts, and OptumRx each maintain separate basal insulin preferred drug tiers, and degludec's preferred status changes annually with rebate negotiations.

Medicare Part D: Covered at $35 per month when on formulary under the IRA cap [8]. Not all Part D formularies include Tresiba; insulin glargine biosimilars are more commonly preferred. Request a plan formulary exception if Tresiba is medically necessary.

Medicaid (Health First Colorado): Covered for type 1 diabetes; requires prior authorization for type 2 diabetes [9]. See the Medicaid section above.

Patients comparing plans should use the formulary lookup tool on each insurer's website or call the plan's pharmacy benefits line directly, because formulary placement in 2026 may differ from what online aggregators report.

Clinical Evidence: Why Physicians Choose Tresiba

The DEVOTE trial enrolled 7,637 adults with type 2 diabetes at high cardiovascular risk and randomized them to insulin degludec or insulin glargine U-100, both titrated to a fasting plasma glucose target of 71 to 90 mg/dL [18]. At a median follow-up of 2.0 years, the primary endpoint of major adverse cardiovascular events (MACE: cardiovascular death, nonfatal myocardial infarction, nonfatal stroke) occurred in 8.5% of degludec patients versus 9.3% of glargine patients (hazard ratio 0.91; 95% CI 0.78, 1.06), meeting the pre-specified noninferiority margin [18].

The secondary hypoglycemia endpoint showed a 40% lower rate of severe hypoglycemic episodes with degludec versus glargine (rate ratio 0.60; 95% CI 0.48, 0.76; P<0.001) [18]. Severe hypoglycemia is defined as an episode requiring the assistance of another person to resolve. That 40% reduction is clinically meaningful for patients with hypoglycemia unawareness, elderly patients, and anyone with an occupation or lifestyle that makes severe hypoglycemic events dangerous.

The SWITCH-1 trial (N=501, type 1 diabetes) showed a 35% reduction in nocturnal confirmed hypoglycemia (plasma glucose <56 mg/dL) with degludec versus glargine U-100 during the maintenance period [3]. SWITCH-2 (N=721, type 2 diabetes) found a 36% reduction in the same endpoint [19]. Both crossover trials were published in Diabetes Care.

For pediatric patients, the BEGIN YOUNG 1 trial (N=350, ages 1, 17) demonstrated non-inferior HbA1c reduction with degludec versus detemir, with a lower rate of nocturnal hypoglycemia [20].

The FDA prescribing information specifies no dose conversion factor when switching from insulin glargine U-100; a unit-to-unit conversion is used, and dose adjustments are made based on individual response [1].

Hypoglycemia Risk and Patient Selection

Not every patient with diabetes needs Tresiba. The incremental benefit over biosimilar insulin glargine is most pronounced in patients with recurrent nocturnal hypoglycemia, hypoglycemia unawareness, or variable injection timing. The DEVOTE investigators reported the hypoglycemia benefit was consistent across subgroups including age, sex, renal function, and HbA1c at baseline [18].

Patients with well-controlled type 2 diabetes on a preferred basal insulin biosimilar (for example, Semglee or Rezvoglar, both FDA-interchangeable with Lantus) may not experience a clinically significant difference in glycemic control, and the cost differential is substantial. Semglee's list price is approximately $98 per month versus Tresiba's $510 [4]. Switching to Tresiba is supported by clinical evidence when hypoglycemia burden justifies it, not simply for convenience.

The ADA's 2024 Standards of Care state: "Insulin degludec and insulin glargine U-300 are associated with less hypoglycemia than insulin glargine U-100 and may be considered for patients with recurrent hypoglycemia" [6]. That recommendation is graded 2A (moderate evidence, strong recommendation) in the ADA framework.

Colorado clinicians using CGM data to document nocturnal hypoglycemia frequency have a measurable clinical rationale for Tresiba formulary exceptions. A pattern of three or more nocturnal events below 54 mg/dL per two-week period on a preferred agent is a documented threshold many PBMs accept for PA approval [21].

Dose Titration and Monitoring for Colorado Patients

Insulin degludec is started at 10 units once daily for insulin-naive type 2 diabetes patients, or at the same total daily basal dose when converting from another basal insulin [1]. Titration toward the fasting plasma glucose target of 71 to 90 mg/dL (or individualized target) proceeds in increments of 2 units every three days, following the simple titration algorithm validated in the BEGIN trials [22].

The long half-life of degludec means steady-state is not reached until three to four days after a dose change. Clinicians and patients must not adjust doses more frequently than every three days or risk stacking [1]. Remote titration via telehealth or asynchronous CGM data review is well-suited to the three-day wait interval, because patients upload data on a schedule rather than making daily phone calls.

Renal dosing: no specific dose adjustment is required, but the FDA label advises more frequent glucose monitoring in patients with renal impairment because of altered insulin clearance and reduced gluconeogenic capacity [1]. The same caution applies to hepatic impairment [1].

Injection site rotation across abdomen, thigh, and upper arm is recommended to reduce lipohypertrophy. Rotating within a single anatomical region (for example, different quadrants of the abdomen) reduces within-day pharmacokinetic variability [23].

Storing Tresiba in Colorado's Climate

Colorado's altitude and temperature swings present specific storage considerations. Tresiba pens in use may be stored at room temperature (below 86°F or 30°C) for up to 56 days, even if the pen has been opened [1]. Unopened pens must be refrigerated at 36, 46°F (2, 8°C) and should not be frozen.

At high-altitude camping or ski trips, temperatures above 86°F are rarely a problem, but freezing risk during Colorado winters is real. Insulin that has been frozen and thawed must be discarded because freezing disrupts the protein structure and produces erratic dosing. Patients traveling in cold conditions should store pens close to the body, not in a car overnight [1].

Switching From Other Basal Insulins to Tresiba

The transition from insulin glargine U-100 or biosimilar to degludec is unit-to-unit with no conversion factor [1]. When switching from insulin glargine U-300 (Toujeo), the prescribing information recommends a 20% dose reduction because glargine U-300 delivers approximately 20% less insulin per unit at equivalent volumes [1].

From NPH insulin, the recommended starting dose of degludec is 80% of the current total daily NPH dose, adjusted for the elimination of the second NPH injection that many patients take at bedtime [1]. Patients switching from a twice-daily basal regimen typically find once-daily degludec simpler to maintain, which may improve adherence. A 2023 review in Diabetes, Obesity and Metabolism found that once-daily basal dosing was associated with a 12 to 18% improvement in adherence compared with twice-daily regimens across pooled observational data [24].

HbA1c should be rechecked six to eight weeks after any basal insulin switch to confirm the transition maintained glycemic control before making further regimen changes.